NORTHAMPTON, MA / ACCESS Newswire / April 8, 2025 / In 2019, Somchai, a Thai native, was 21 years old and faced a double ...

Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground ...

In the most recent trading session, Gilead Sciences (GILD) closed at $111.88, indicating a +0.54% shift from the previous trading day.

South Florida, an area with the highest rate of HIV/AIDS in the country, is already starting to feel the effects of the Trump ...

Georgia lawmakers are hoping to pass a bill before the legislative session ends Friday that would allow pharmacists to ...

Overview of HIV Drugs MarketThe Global HIV Drugs Market is valued at USD 34.75 Billion in 2024 and is projected to reach a ...

Human immunodeficiency virus, if untreated, causes acquired immunodeficiency syndrome (AIDS), and death. HIV is almost entirely preventable by using condoms, or by taking PrEP drugs. PrEP drugs do not ...

In a phase 2 trial, an antiretroviral combination developed by Gilead Sciences and MSD suppressed HIV with a single weekly oral dose, raising the hope of a new treatment option for patients.

Explore the top-performing Nasdaq 100 stocks this year as the index moves into a technical bear market this year.